Standardized classification and reporting of glomerulonephritis
https://doi.org/10.24884/1561-6274-2019-23-4-27-35
Abstract
A kidney biopsy is done to determine the etiology of the glomerulonephritis (GN) and the severity of the lesion, to identify whether other lesions, related to or not related to the GN, are present on the kidney biopsy and finally to ascertain the extent of chronicity of the GN. The etiology of GN is based on the classification of GN into five groups: immune complex-mediated GN, antineutrophil cytoplasmic antibody (ANCA)-associated GN, anti-glomerular basement membrane (GBM) GN, monoclonal immunoglobulin-mediated GN and C3 glomerulopathy. Immune complex GN includes multiple specific diseases such as lupus nephritis, IgA nephropathy, infection-related GN and fibrillary GN. ANCA GN, anti-GBM GN and C3 glomerulopathy are specific diseases in themselves, while monoclonal Ig GN includes proliferative GN with monoclonal Ig deposits and monoclonal Ig deposition disease. Thus identification of the class of GN and within it the specific disease determines the etiology of GN. Ancillary studies may be required to confirm the etiology of GN. The severity of the GN is revealed by the pattern of injury, such as crescentic, necrotizing, diffuse proliferative, exudative, membranoproliferative, mesangial proliferative or a sclerosing GN. Secondary diagnosis either related or unrelated to the GN, such as diabetic glomerulosclerosis, acute tubular necrosis or thrombotic microangiopathy, may also be present. The secondary diagnosis may sometimes be the reason for the kidney biopsy. The chronicity of GN is determined by evaluating the extent of glomerulosclerosis, tubular atrophy and interstitial fibrosis and vascular sclerosis present on the biopsy. This review summarizes the approach to standardizing a kidney biopsy report that includes these components in a logical and sequential manner.
Translation by D.A. Mayer, T.O. Muzhetckaya, A.O. Mukhametdinova, M.S. Khrabrova.
About the Authors
S. Sethi
Mayo Clinic
United States
United States
Department of Internal Medicine, Division of Anatomic Pathology, Department of Laboratory Medicine and Pathology
Rochester, MN
F. C. Fervenza
Mayo Clinic
United States
United States
Division of Nephrology and Hypertension
Mayo Clinic, RochesterReferences
1. Sethi S, Fervenza FC. Membranoproliferative glomerulonephritis: a new look at an old entity. N Engl J Med 2012; 366 (12): 1119-1131. doi: 10.1056/NEJMra1108178
2. Sethi S, Fervenza FC. Membranoproliferative glomerulonephritis: pathogenetic heterogeneity and proposal for a new classification. Semin Nephrol 2011; 31 (4): 341-348. doi: 10.1016/j.semnephrol.2011.06.005
3. Sethi S. Etiology-based diagnostic approach to proliferative glomerulonephritis. Am J Kidney Dis 2014; 63 (4): 561-566. doi: 10.1053/j.ajkd.2013.11.019
4. Sethi S, Haas M, Markowitz GS et al. Mayo Clinic/Renal Pathology Society consensus report on pathologic classification, diagnosis, and reporting of GN. J Am Soc Nephrol 2016; 27 (5): 1278-1287. doi: 10.1681/ASN.2015060612
5. Weening JJ, D’Agati VD, Schwartz MM et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004; 15 (2): 241-250. doi: -
6. Cattran D, Coppo R, Cook H et al. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int 2009; 76 (5): 534-545. doi: 10.1038/ki.2009.243
7. Nasr SH, Valeri AM, Cornell LD et al. Fibrillary glomerulonephritis: a report of 66 cases from a single institution. Clin J Am Soc Nephrol 2011; 6 (4): 775-784. doi: 10.2215/CJN.08300910
8. Nasr SH, Radhakrishnan J, D’Agati VD. Bacterial infection-related glomerulonephritis in adults. Kidney Int 2013; 83 (5): 792-803. doi: 10.1038/ki.2012.407
9. Jennette JC, Falk RJ. Pathogenesis of antineutrophil cytoplasmic autoantibody-mediated disease. Nat Rev Rheumatol 2014; 10 (8): 463-473. doi: 10.1038/nrrheum.2014.103
10. Falk R, Nachman P, Hogan S et al. ANCA glomerulonephritis and vasculitis: a Chapel Hill perspective. Semin Nephrol 2000 (3); 20: 233-243. doi: -
11. Nasr SH, Satoskar A, Markowitz GS et al. Proliferative glomerulonephritis with monoclonal IgG deposits. J Am Soc Nephrol 2009; 20 (9): 2055-2064. doi: 10.1681/ASN.2009010110
12. Sethi S, Zand L, Leung N et al. Membranoproliferative glomerulonephritis secondary to monoclonal gammopathy. Clin J Am Soc Nephrol 2010; 5 (5): 770-782. doi: 10.2215/CJN.06760909
13. Sethi S, Rajkumar SV. Monoclonal gammopathy-associat-ed proliferative glomerulonephritis. Mayo Clin Proc 2013; 88 (11): 1284-1293. doi: 10.1016/j.mayocp.2013.08.002
14. Lin J, Markowitz GS, Valeri AM et al. Renal monoclonal immunoglobulin deposition disease: the disease spectrum. J Am Soc Nephrol 2001; 12 (7): 1482-1492. doi: -
15. Nasr SH, Fidler ME, Cornell LD et al. Immunotactoid glomerulopathy: clinicopathologic and proteomic study. Nephrol Dial Transplant 2012; 27 (11): 4137-4146. doi: 10.1093/ndt/gfs348
16. Servais A, Fremeaux-Bacchi V, Lequintrec M et al. Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome. J Med Genet 2007; 44 (3): 193-199. doi: -
17. Pickering MC, D’Agati VD, Nester CM et al. C3 glomerulopathy: consensus report. Kidney Int 2013; 84 (6): 1079-1089. doi: 10.1038/ki.2013.377
18. Sethi S, Fervenza FC, Zhang Y et al. C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up. Kidney Int 2012; 82 (4): 465-473. doi:10.1038/ki2012.212
19. Fakhouri F, Fremeaux-Bacchi V, Noel L-H et al. C3 glomerulopathy: a new classification. Nat Rev Nephrol 2010; 6 (8): 494-499. doi: 10.1038/nrneph.2010.85
20. Hou J, Markowitz GS, Bomback AS et al. Toward a working definition of C3 glomerulopathy by immunofluorescence. Kidney Int 2014; 85 (2): 450 -456. doi: 10.1038/ki.2013.340
21. Nasr SH, Galgano SJ, Markowitz GS et al. Immunofluorescence on pronase-digested paraffin sections: a valuable salvage technique for renal biopsies. Kidney Int 2006; 70 (12): 2148-2151. doi: 10.1038/sj.ki.5001990
22. Larsen CP, Messias NC, Walker PD et al. Membranoproliferative glomerulonephritis with masked monotypic immunoglobulin deposits. Kidney Int 2015; 88 (4): 867-873. doi: 10.1038/ki.2015.195
23. Sethi S, Nasr SH, De Vriese AS et al. C4d as a diagnostic tool in proliferative GN. J Am Soc Nephrol 2015; 26 (11): 28522859. doi: 10.1681/ASN.2014040406
24. Sethi S, Rajkumar SV, D’Agati VD. The complexity and heterogeneity of monoclonal immunoglobulin-associated renal diseases. J Am Soc Nephrol 2018; 29 (7): 1810-1823. doi: 10.1681/ASN.2017121319
25. Dasari S, Alexander MP, Vrana JA et al. DNAJ heat shock protein family B member 9 is a novel biomarker for fibrillary GN. J Am Soc Nephrol 2018; 29 (1): 51-56. doi: 10.1681/ASN.2017030306
26. Jain D, Green JA, Bastacky S et al. Membranoprolif-erative glomerulonephritis: the role for laser microdissection and mass spectrometry. Am J Kidney Dis 2014; 63 (2): 324-328. doi: 10.1053/j.ajkd.2013.09.007
27. Royal V, Quint P, Leblanc M et al. IgD heavy-chain deposition disease: detection by laser microdissection and mass spectrometry. J Am Soc Nephrol 2015; 26 (2): 784-790. doi: 10.1681/ASN.2014050481
28. Sethi S, Vrana JA, Theis JD et al. Mass spectrometry based proteomics in the diagnosis of kidney disease. Curr Opin Nephrol Hypertens 2013; 22 (3): 273-280. doi: 10.1097/MNH.0b013e32835fe37c
29. Roberts IS, Cook H, Troyanov S et al. The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int 2009; 76 (5): 546-556. doi: 10.1038/ki.2009.168
30. Bajema IM, Wilhelmus S, Alper CE. Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney Int 2018; 93 (4): 789-796. doi: 10.1016/j.kint.2017.11.023
31. Berden AE, Ferrario F, Hagen EC et al. Histopathologic classification of ANCA-associated glomerulonephritis. J Am Soc Nephrol 2010; 21(10): 1628-1636. doi: 10.1681/ASN.2010050477
32. Sethi S, D’Agati VD, Nast CC et al. A proposal for standardized grading of chronic changes in native kidney biopsy specimens. Kidney Int 2017; 91 (4): 787-789. doi: 10.1016/j.kint.2017.01.002
33. Bomback AS, Santoriello D, Avasare RS et al. C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy. Kidney Int 2018; 93 (4): 977-985. doi: 10.1016/j.kint.2017.10.022
34. Glassock RJ, Bleyer AJ, Bargman JM et al. The 2010 nephrology quiz and questionnaire: part 2. Clin J Am Soc Nephrol 2011; 6 (10): 2534-2547. doi: 10.2215/CJN.06500711
Review
For citations:
Sethi S., Fervenza F.C. Standardized classification and reporting of glomerulonephritis. Nephrology (Saint-Petersburg). 2019;23(4):27-35. (In Russ.) https://doi.org/10.24884/1561-6274-2019-23-4-27-35
Views:
2899
Email this article 